citalopram has been researched along with Stroke in 66 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "4 %) received citalopram and median (IQR) prestroke PASE score was 132." | 9.69 | Impact of prestroke physical activity and citalopram treatment on poststroke depressive symptoms: a secondary analysis of data from the TALOS randomised controlled trial in Denmark. ( Andersen, G; Blauenfeldt, RA; Damsbo, AG; Johnsen, SP; Mortensen, JK; Vestergaard, SB, 2023) |
| "The effect of escitalopram on PSD may be more prominent in patients with particular depressive symptoms and stroke lesion locations, suggesting the need for tailored treatment strategies." | 9.41 | Post-Stroke Depressive Symptoms: Varying Responses to Escitalopram by Individual Symptoms and Lesion Location. ( Ahn, SH; Cha, JK; Chang, DI; Choi-Kwon, S; Heo, JH; Kim, DE; Kim, HY; Kim, J; Kim, JS; Kim, JY; Kim, MS; Kim, S; Koh, SH; Kwon, DY; Lee, BC; Lee, EJ; Lee, J; Lee, JS; Park, JH; Park, SW; Seo, WK; Sohn, SI, 2021) |
| "This study aimed to investigate whether the routine administration of escitalopram for three months would improve the prognosis of patients with ischemic stroke and decrease the plasma copeptin level." | 9.34 | Effects of the prophylactic use of escitalopram on the prognosis and the plasma copeptin level in patients with acute cerebral infarction. ( Cao, JX; Chen, JC; Liu, L; Sun, YT; Wang, Y; Zeng, QH, 2020) |
| "We evaluated the effect of SSRI treatment on platelet aggregation in patients with ischaemic stroke and included patients from the randomized double-blind controlled study of citalopram in acute ischaemic stroke (TALOS)." | 9.30 | Antiplatelet effects of citalopram in patients with ischaemic stroke: A randomized, placebo-controlled, double-blind study. ( Andersen, G; Grove, EL; Johnsen, SP; Kraglund, KL; Mortensen, JK, 2019) |
| "There was no significant difference between citalopram and fluoxetine in facilitating post-stroke motor recovery in ischemic stroke patients." | 9.27 | The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial. ( Asadollahi, M; Karimialavijeh, E; Khanmoradi, Z; Ramezani, M, 2018) |
| "This study re-examined patients from a 1-year randomized controlled double-blind trial of escitalopram, problem-solving therapy (PST), or placebo to prevent depression among patients less than 3 months after a stroke." | 9.24 | Prevention of Poststroke Mortality Using Problem-Solving Therapy or Escitalopram. ( Jorge, RE; Long, J; Robinson, RG, 2017) |
| "Escitalopram did not significantly reduce moderate or severe depressive symptoms in patients with acute stroke." | 9.24 | Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. ( Ahn, SH; Cha, JK; Chang, DI; Choi-Kwon, S; Heo, JH; Kim, DE; Kim, HY; Kim, J; Kim, JS; Kim, JY; Kim, S; Koh, SH; Kwon, DY; Lee, BC; Lee, EJ; Lee, J; Park, JH; Park, SW; Seo, WK; Sohn, SI, 2017) |
| "TALOS is an investigator-initiated, national multicenter randomized- and placebo-controlled, double-blind trial testing citalopram in acute ischemic stroke." | 9.20 | TALOS: a multicenter, randomized, double-blind, placebo-controlled trial to test the effects of citalopram in patients with acute stroke. ( Andersen, G; Grove, EL; Johnsen, SP; Kraglund, KL; Mortensen, JK, 2015) |
| "Escitalopram or PST was significantly more effective in preventing new onset of apathy following stroke compared with placebo." | 9.17 | Prevention of poststroke apathy using escitalopram or problem-solving therapy. ( Arndt, S; Fonzetti, P; Hegel, MT; Jang, M; Jorge, RE; Mikami, K; Moser, DJ; Robinson, RG; Small, SL; Solodkin, A, 2013) |
| "The authors sought to determine the relative efficacy and tolerability of duloxetine versus citalopram and sertraline in the treatment of poststroke depression (PSD), anxiety, and fatigue." | 9.16 | Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue. ( Karaiskos, D; Paparrigopoulos, T; Spengos, K; Tzavellas, E; Vassilopoulou, S, 2012) |
| "Discontinuation of escitalopram may increase poststroke depressive symptoms." | 9.15 | Increased frequency of first-episode poststroke depression after discontinuation of escitalopram. ( Arndt, S; Fonzetti, P; Hegel, MT; Jang, M; Jorge, RE; Mikami, K; Moser, DJ; Robinson, RG; Small, SL; Solodkin, A, 2011) |
| "When compared with patients who received placebo or underwent Problem Solving Therapy, stroke patients who received escitalopram showed improvement in global cognitive functioning, specifically in verbal and visual memory functions." | 9.14 | Escitalopram and enhancement of cognitive recovery following stroke. ( Acion, L; Adams, HP; Jorge, RE; Moser, D; Robinson, RG, 2010) |
| "Patients who received placebo were significantly more likely to develop depression than individuals who received escitalopram (11 major and 2 minor cases of depression [22." | 9.13 | Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. ( Acion, L; Arndt, S; Fonzetti, P; Hegel, M; Jorge, RE; Moser, DJ; Robinson, RG; Small, SL; Solodkin, A, 2008) |
| "The effect of a combination of light therapy and citalopram in stroke victims receiving citalopram was examined by use of two different doses of light therapy under double-blind conditions." | 9.12 | Dose response to adjunctive light therapy in citalopram-treated patients with post-stroke depression. A randomised, double-blind pilot study. ( Andersen, G; Bech, P; Jarden, JO; Martiny, K; Søndergaard, MP, 2006) |
| " Significant decreases on Hamilton Depression Scale scores were observed in favor of citalopram when compared to other SSRIs after 4-, 6-week treatment [SMD = -." | 8.98 | Efficacy and Safety of Citalopram for the Treatment of Poststroke Depression: A Meta-Analysis. ( Cui, M; Huang, CY; Wang, F, 2018) |
| "02), and the Hamilton Depression Scale with citalopram was lower than that found with other SSRIs (SMD -0." | 8.91 | Efficacy and Safety of Citalopram in Treating Post-Stroke Depression: A Meta-Analysis. ( Ding, L; Hong, H; Huang, X; Tan, S, 2015) |
| "This study aims to assess the efficacy and safety of citalopram for the treatment of patients with post-stroke depression (PSD)." | 7.96 | Does citalopram effectively treat post-stroke depression?: A protocol for systematic review and meta analysis. ( Hu, J; Ma, L; Yang, ZY, 2020) |
| "This retrospective study investigated the efficacy and safety of escitalopram oxalate (ESO) for the treatment of post-stroke depression (PSD)." | 7.88 | Efficacy of escitalopram oxalate for patients with post-stroke depression. ( Jiang, P; Xu, JH, 2018) |
| "gov NCT01278498), a randomised, placebo-controlled, double-blind trial examining the efficacy of escitalopram on emotional and neurological disturbances after acute stroke." | 7.88 | Serotonin transporter gene polymorphisms may be associated with poststroke neurological recovery after escitalopram use. ( Cha, JK; Chang, DI; Heo, JH; Kim, DE; Kim, HY; Kim, J; Kim, JS; Kim, YJ; Lee, BC; Lee, EJ; Lee, J; Oh, MS; Park, JH; Park, SW; Seo, WK; Sohn, SI, 2018) |
| "Citalopram is a safe and tolerable medication in patients with acute IS, which could improve the outcome in these patients." | 6.84 | Efficacy of Citalopram on Acute Ischemic Stroke Outcome: A Randomized Clinical Trial. ( Abbaszade, Z; Ghazanfari Amlashi, S; Golzari, SEJ; Hashemilar, M; Nikanfar, M; Rikhtegar, R; Sadeghi Bazargani, H; Sadeghihokmabadi, E; Savadi Oskouie, D; Sharifipour, E, 2017) |
| "Citalopram-treated animals (n = 13) showed a significant increase in impaired forepaw use in the staircase task compared with saline-treated animals (n = 12) 2, 3 and 7 weeks post stroke but no difference in neurological score at any time point examined." | 5.72 | Delayed citalopram administration reduces brain inflammation and enhances skilled motor function after ischaemic stroke in 'MacGreen' mice. ( Bennet, L; Chen, S; McGregor, AL, 2022) |
| "4 %) received citalopram and median (IQR) prestroke PASE score was 132." | 5.69 | Impact of prestroke physical activity and citalopram treatment on poststroke depressive symptoms: a secondary analysis of data from the TALOS randomised controlled trial in Denmark. ( Andersen, G; Blauenfeldt, RA; Damsbo, AG; Johnsen, SP; Mortensen, JK; Vestergaard, SB, 2023) |
| "The effect of escitalopram on PSD may be more prominent in patients with particular depressive symptoms and stroke lesion locations, suggesting the need for tailored treatment strategies." | 5.41 | Post-Stroke Depressive Symptoms: Varying Responses to Escitalopram by Individual Symptoms and Lesion Location. ( Ahn, SH; Cha, JK; Chang, DI; Choi-Kwon, S; Heo, JH; Kim, DE; Kim, HY; Kim, J; Kim, JS; Kim, JY; Kim, MS; Kim, S; Koh, SH; Kwon, DY; Lee, BC; Lee, EJ; Lee, J; Lee, JS; Park, JH; Park, SW; Seo, WK; Sohn, SI, 2021) |
| "Citalopram treatment had no significant effect on infarct formation or edema 3 days after stroke; however, citalopram-treated mice had better functional recovery than saline-treated controls 3 and 14 days after stroke in the adhesive removal test." | 5.39 | Citalopram enhances neurovascular regeneration and sensorimotor functional recovery after ischemic stroke in mice. ( Espinera, AR; Gu, X; Ogle, ME; Wei, L, 2013) |
| "gov, NCT01278498), a randomized, placebo-controlled, double-blind trial that examined the efficacy of escitalopram for 3 months on depression in patients with acute stroke." | 5.34 | Depressive Symptoms in Stroke Patients: Are There Sex Differences? ( Ahn, SH; Cha, JK; Chang, DI; Choi-Kwon, S; Heo, JH; Kim, DE; Kim, HY; Kim, J; Kim, JS; Kim, JY; Kim, S; Koh, SH; Kwon, DY; Lee, BC; Lee, EJ; Lee, J; Park, JH; Park, SW; Seo, WK; Sohn, SI, 2020) |
| "This study aimed to investigate whether the routine administration of escitalopram for three months would improve the prognosis of patients with ischemic stroke and decrease the plasma copeptin level." | 5.34 | Effects of the prophylactic use of escitalopram on the prognosis and the plasma copeptin level in patients with acute cerebral infarction. ( Cao, JX; Chen, JC; Liu, L; Sun, YT; Wang, Y; Zeng, QH, 2020) |
| "We evaluated the effect of SSRI treatment on platelet aggregation in patients with ischaemic stroke and included patients from the randomized double-blind controlled study of citalopram in acute ischaemic stroke (TALOS)." | 5.30 | Antiplatelet effects of citalopram in patients with ischaemic stroke: A randomized, placebo-controlled, double-blind study. ( Andersen, G; Grove, EL; Johnsen, SP; Kraglund, KL; Mortensen, JK, 2019) |
| "SERT gene polymorphisms in 270 non-depressed first-ever acute ischemic stroke patients randomized to citalopram, n = 130, or placebo, n = 140, were investigated." | 5.30 | Serotonergic Regulation and Cognition after Stroke: The Role of Antidepressant Treatment and Genetic Variation. ( Andersen, G; Buttenschøn, HN; Damsbo, AG; Johnsen, SP; Kraglund, KL; Mortensen, JK, 2019) |
| "There was no significant difference between citalopram and fluoxetine in facilitating post-stroke motor recovery in ischemic stroke patients." | 5.27 | The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial. ( Asadollahi, M; Karimialavijeh, E; Khanmoradi, Z; Ramezani, M, 2018) |
| "Serving as a pilot study of poststroke pharmacotherapy, the present investigation was intended to establish the effect of a single dose of escitalopram on motor task performance in normal volunteers." | 5.27 | The effect of a single dose of escitalopram on sensorimotor networks. ( Eap, CB; Kägi, G; Krammer, W; Missimer, JH; Weder, BJ; Weisstanner, C; Wiest, R, 2018) |
| "This study re-examined patients from a 1-year randomized controlled double-blind trial of escitalopram, problem-solving therapy (PST), or placebo to prevent depression among patients less than 3 months after a stroke." | 5.24 | Prevention of Poststroke Mortality Using Problem-Solving Therapy or Escitalopram. ( Jorge, RE; Long, J; Robinson, RG, 2017) |
| "Escitalopram did not significantly reduce moderate or severe depressive symptoms in patients with acute stroke." | 5.24 | Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. ( Ahn, SH; Cha, JK; Chang, DI; Choi-Kwon, S; Heo, JH; Kim, DE; Kim, HY; Kim, J; Kim, JS; Kim, JY; Kim, S; Koh, SH; Kwon, DY; Lee, BC; Lee, EJ; Lee, J; Park, JH; Park, SW; Seo, WK; Sohn, SI, 2017) |
| "TALOS is an investigator-initiated, national multicenter randomized- and placebo-controlled, double-blind trial testing citalopram in acute ischemic stroke." | 5.20 | TALOS: a multicenter, randomized, double-blind, placebo-controlled trial to test the effects of citalopram in patients with acute stroke. ( Andersen, G; Grove, EL; Johnsen, SP; Kraglund, KL; Mortensen, JK, 2015) |
| "Escitalopram or PST was significantly more effective in preventing new onset of apathy following stroke compared with placebo." | 5.17 | Prevention of poststroke apathy using escitalopram or problem-solving therapy. ( Arndt, S; Fonzetti, P; Hegel, MT; Jang, M; Jorge, RE; Mikami, K; Moser, DJ; Robinson, RG; Small, SL; Solodkin, A, 2013) |
| "The authors sought to determine the relative efficacy and tolerability of duloxetine versus citalopram and sertraline in the treatment of poststroke depression (PSD), anxiety, and fatigue." | 5.16 | Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue. ( Karaiskos, D; Paparrigopoulos, T; Spengos, K; Tzavellas, E; Vassilopoulou, S, 2012) |
| "Discontinuation of escitalopram may increase poststroke depressive symptoms." | 5.15 | Increased frequency of first-episode poststroke depression after discontinuation of escitalopram. ( Arndt, S; Fonzetti, P; Hegel, MT; Jang, M; Jorge, RE; Mikami, K; Moser, DJ; Robinson, RG; Small, SL; Solodkin, A, 2011) |
| "When compared with patients who received placebo or underwent Problem Solving Therapy, stroke patients who received escitalopram showed improvement in global cognitive functioning, specifically in verbal and visual memory functions." | 5.14 | Escitalopram and enhancement of cognitive recovery following stroke. ( Acion, L; Adams, HP; Jorge, RE; Moser, D; Robinson, RG, 2010) |
| "Patients who received placebo were significantly more likely to develop depression than individuals who received escitalopram (11 major and 2 minor cases of depression [22." | 5.13 | Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. ( Acion, L; Arndt, S; Fonzetti, P; Hegel, M; Jorge, RE; Moser, DJ; Robinson, RG; Small, SL; Solodkin, A, 2008) |
| "Based on available RCTs of fluoxetine and citalopram, SSRIs used for 6 months doubled the risk of fractures in stroke survivors." | 5.12 | Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis. ( Almeida, OP; Hankey, GJ; Jones, JS; Kimata, R, 2021) |
| "The effect of a combination of light therapy and citalopram in stroke victims receiving citalopram was examined by use of two different doses of light therapy under double-blind conditions." | 5.12 | Dose response to adjunctive light therapy in citalopram-treated patients with post-stroke depression. A randomised, double-blind pilot study. ( Andersen, G; Bech, P; Jarden, JO; Martiny, K; Søndergaard, MP, 2006) |
| "Escitalopram was associated with a quicker relief of depression, but mirtazapine was probably the best option when it comes to the efficacy of 8-week treatment duration." | 5.05 | Comparative efficacy of nine antidepressants in treating Chinese patients with post-stroke depression: A network meta-analysis. ( Li, X; Zhang, C, 2020) |
| " Significant decreases on Hamilton Depression Scale scores were observed in favor of citalopram when compared to other SSRIs after 4-, 6-week treatment [SMD = -." | 4.98 | Efficacy and Safety of Citalopram for the Treatment of Poststroke Depression: A Meta-Analysis. ( Cui, M; Huang, CY; Wang, F, 2018) |
| "02), and the Hamilton Depression Scale with citalopram was lower than that found with other SSRIs (SMD -0." | 4.91 | Efficacy and Safety of Citalopram in Treating Post-Stroke Depression: A Meta-Analysis. ( Ding, L; Hong, H; Huang, X; Tan, S, 2015) |
| "Randomized controlled trials have demonstrated the efficacy of sertraline, citalopram and nortriptyline to treat post-stroke depression." | 4.84 | Antidepressant therapy in post-stroke depression. ( Mizrahi, R; Power, BD; Starkstein, SE, 2008) |
| "This study aims to assess the efficacy and safety of citalopram for the treatment of patients with post-stroke depression (PSD)." | 3.96 | Does citalopram effectively treat post-stroke depression?: A protocol for systematic review and meta analysis. ( Hu, J; Ma, L; Yang, ZY, 2020) |
| "This retrospective study investigated the efficacy and safety of escitalopram oxalate (ESO) for the treatment of post-stroke depression (PSD)." | 3.88 | Efficacy of escitalopram oxalate for patients with post-stroke depression. ( Jiang, P; Xu, JH, 2018) |
| "gov NCT01278498), a randomised, placebo-controlled, double-blind trial examining the efficacy of escitalopram on emotional and neurological disturbances after acute stroke." | 3.88 | Serotonin transporter gene polymorphisms may be associated with poststroke neurological recovery after escitalopram use. ( Cha, JK; Chang, DI; Heo, JH; Kim, DE; Kim, HY; Kim, J; Kim, JS; Kim, YJ; Lee, BC; Lee, EJ; Lee, J; Oh, MS; Park, JH; Park, SW; Seo, WK; Sohn, SI, 2018) |
| "Depression is a common complication after stroke and is closely related to the poor prognosis of stroke." | 3.01 | Clinical efficacy of Danzhi Xiaoyao Powder in the treatment of post-stroke depression: A protocol for randomized, double-blind clinical study. ( Ding, C; Gao, L; Guo, M; Wang, X; Xu, M; Xu, W; Yao, J, 2021) |
| "Citalopram is a safe and tolerable medication in patients with acute IS, which could improve the outcome in these patients." | 2.84 | Efficacy of Citalopram on Acute Ischemic Stroke Outcome: A Randomized Clinical Trial. ( Abbaszade, Z; Ghazanfari Amlashi, S; Golzari, SEJ; Hashemilar, M; Nikanfar, M; Rikhtegar, R; Sadeghi Bazargani, H; Sadeghihokmabadi, E; Savadi Oskouie, D; Sharifipour, E, 2017) |
| " A selective serotonergic drug (citalopram) or a placebo was administered using a mean dosage of 10 mg/day in combination with physiotherapy." | 2.74 | A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. ( Acler, M; Fiaschi, A; Manganotti, P; Robol, E, 2009) |
| "Stroke is the major cause of adult disability." | 2.48 | Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. ( Claxton, A; Hackett, ML; Hankey, GJ; Hsieh, CF; Kutlubaev, MA; Lee, R; Mead, GE, 2012) |
| "Citalopram-treated animals (n = 13) showed a significant increase in impaired forepaw use in the staircase task compared with saline-treated animals (n = 12) 2, 3 and 7 weeks post stroke but no difference in neurological score at any time point examined." | 1.72 | Delayed citalopram administration reduces brain inflammation and enhances skilled motor function after ischaemic stroke in 'MacGreen' mice. ( Bennet, L; Chen, S; McGregor, AL, 2022) |
| "Citalopram treatment had no significant effect on infarct formation or edema 3 days after stroke; however, citalopram-treated mice had better functional recovery than saline-treated controls 3 and 14 days after stroke in the adhesive removal test." | 1.39 | Citalopram enhances neurovascular regeneration and sensorimotor functional recovery after ischemic stroke in mice. ( Espinera, AR; Gu, X; Ogle, ME; Wei, L, 2013) |
| "Early diagnosis and effective treatment of depression will help the rehabilitation outcome of stroke patients." | 1.35 | Depression and functional outcome after stroke: the effect of antidepressant therapy on functional recovery. ( Bilge, C; Koçer, A; Koçer, E; Türk Börü, U, 2008) |
| " CMS induced behavioural changes in the ischemic animals, including decreased locomotor and rearing activity and reduced sucrose preference (compared with baseline, control and stroke groups respectively), all these behaviours were reversed by chronic administration of citalopram." | 1.35 | Anhedonia and activity deficits in rats: impact of post-stroke depression. ( Chen, BA; Guo, YJ; Teng, GJ; Wang, SH; Zhang, ZJ; Zhou, H, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (33.33) | 29.6817 |
| 2010's | 32 (48.48) | 24.3611 |
| 2020's | 12 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, C | 1 |
| Xu, M | 1 |
| Gao, L | 1 |
| Wang, X | 1 |
| Xu, W | 1 |
| Guo, M | 1 |
| Yao, J | 1 |
| Chen, S | 1 |
| Bennet, L | 1 |
| McGregor, AL | 1 |
| Ece Çetin, F | 1 |
| Kumral, E | 1 |
| Saffet Gönül, A | 1 |
| Nezih Özdemir, H | 1 |
| Orman, M | 1 |
| Kalbouneh, HM | 1 |
| Toubasi, AA | 1 |
| Albustanji, FH | 1 |
| Obaid, YY | 1 |
| Al-Harasis, LM | 1 |
| Taghizadeh-Ghehi, M | 1 |
| Emami, M | 1 |
| Heidari, K | 1 |
| Vestergaard, SB | 1 |
| Damsbo, AG | 3 |
| Blauenfeldt, RA | 1 |
| Johnsen, SP | 5 |
| Andersen, G | 7 |
| Mortensen, JK | 5 |
| Kraglund, KL | 4 |
| Grove, EL | 3 |
| Lee, EJ | 4 |
| Kim, JS | 4 |
| Chang, DI | 4 |
| Park, JH | 4 |
| Ahn, SH | 3 |
| Cha, JK | 4 |
| Heo, JH | 4 |
| Sohn, SI | 4 |
| Lee, BC | 4 |
| Kim, DE | 4 |
| Kim, HY | 4 |
| Kim, S | 3 |
| Kwon, DY | 3 |
| Kim, J | 5 |
| Seo, WK | 4 |
| Lee, J | 4 |
| Park, SW | 4 |
| Koh, SH | 3 |
| Kim, JY | 3 |
| Choi-Kwon, S | 3 |
| Li, X | 1 |
| Zhang, C | 1 |
| Hu, J | 1 |
| Ma, L | 1 |
| Yang, ZY | 1 |
| Kim, MS | 1 |
| Lee, JS | 1 |
| Cao, JX | 1 |
| Liu, L | 1 |
| Sun, YT | 1 |
| Zeng, QH | 1 |
| Wang, Y | 1 |
| Chen, JC | 1 |
| Jones, JS | 1 |
| Kimata, R | 1 |
| Almeida, OP | 1 |
| Hankey, GJ | 2 |
| Savadi Oskouie, D | 1 |
| Sharifipour, E | 1 |
| Sadeghi Bazargani, H | 1 |
| Hashemilar, M | 1 |
| Nikanfar, M | 1 |
| Ghazanfari Amlashi, S | 1 |
| Abbaszade, Z | 1 |
| Sadeghihokmabadi, E | 1 |
| Rikhtegar, R | 1 |
| Golzari, SEJ | 1 |
| Sun, Y | 1 |
| Liang, Y | 1 |
| Jiao, Y | 1 |
| Lin, J | 1 |
| Qu, H | 1 |
| Xu, J | 1 |
| Zhao, C | 1 |
| Oh, MS | 1 |
| Kim, YJ | 1 |
| Xu, JH | 1 |
| Jiang, P | 1 |
| Gupta, S | 1 |
| Upadhayay, D | 1 |
| Sharma, U | 1 |
| Jagannathan, NR | 1 |
| Gupta, YK | 1 |
| Asadollahi, M | 1 |
| Ramezani, M | 1 |
| Khanmoradi, Z | 1 |
| Karimialavijeh, E | 1 |
| Kim, Y | 1 |
| Weisstanner, C | 1 |
| Kägi, G | 1 |
| Krammer, W | 1 |
| Eap, CB | 1 |
| Wiest, R | 1 |
| Missimer, JH | 1 |
| Weder, BJ | 1 |
| Cui, M | 1 |
| Huang, CY | 1 |
| Wang, F | 1 |
| Modrau, B | 1 |
| Simonsen, SA | 1 |
| Iversen, HK | 1 |
| Madsen, M | 1 |
| Buttenschøn, HN | 1 |
| Espinera, AR | 1 |
| Ogle, ME | 1 |
| Gu, X | 1 |
| Wei, L | 1 |
| Madani, Y | 1 |
| Azad, S | 1 |
| Nachev, P | 1 |
| Collas, D | 1 |
| Mikami, K | 3 |
| Jorge, RE | 6 |
| Moser, DJ | 4 |
| Arndt, S | 5 |
| Jang, M | 3 |
| Solodkin, A | 4 |
| Small, SL | 4 |
| Fonzetti, P | 4 |
| Hegel, MT | 3 |
| Robinson, RG | 7 |
| Wang, SS | 1 |
| Wang, YG | 1 |
| Chen, HY | 1 |
| Wu, ZP | 1 |
| Xie, HG | 1 |
| Affan, M | 1 |
| Shaikh, Q | 1 |
| Kamal, AK | 1 |
| Lin, DH | 1 |
| Zhang, XR | 1 |
| Ye, DQ | 1 |
| Xi, GJ | 1 |
| Hui, JJ | 1 |
| Liu, SS | 1 |
| Li, LJ | 1 |
| Zhang, ZJ | 3 |
| Tan, S | 1 |
| Huang, X | 1 |
| Ding, L | 1 |
| Hong, H | 1 |
| Gao, J | 1 |
| Lin, M | 1 |
| Zhao, J | 1 |
| Bi, S | 1 |
| Ni, Z | 1 |
| Shang, X | 1 |
| Kumar, S | 1 |
| Long, J | 1 |
| Wang, SH | 2 |
| Guo, YJ | 2 |
| Zhou, H | 1 |
| Teng, GJ | 2 |
| Chen, BA | 2 |
| Lacasse, J | 1 |
| Leo, J | 1 |
| Dettling, M | 1 |
| Opgen-Rhein, C | 1 |
| Anghelescu, I | 1 |
| Schulte-Herbrüggen, O | 1 |
| Röpke, S | 1 |
| Rasmussen, A | 1 |
| Hanash, JA | 1 |
| Bech, P | 2 |
| Tallelli, P | 1 |
| Werring, DJ | 1 |
| Acler, M | 1 |
| Robol, E | 1 |
| Fiaschi, A | 1 |
| Manganotti, P | 1 |
| Gusev, EI | 2 |
| Bogolepova, AN | 2 |
| Acion, L | 2 |
| Moser, D | 1 |
| Adams, HP | 1 |
| Aggarwal, A | 2 |
| Kumar, R | 2 |
| Sharma, RC | 1 |
| Sharma, DD | 2 |
| Sharma, R | 1 |
| Kronenberg, G | 1 |
| Balkaya, M | 1 |
| Prinz, V | 1 |
| Gertz, K | 1 |
| Ji, S | 1 |
| Kirste, I | 1 |
| Heuser, I | 1 |
| Kampmann, B | 1 |
| Hellmann-Regen, J | 1 |
| Gass, P | 1 |
| Sohr, R | 1 |
| Hellweg, R | 1 |
| Waeber, C | 1 |
| Juckel, G | 1 |
| Hörtnagl, H | 1 |
| Stumm, R | 1 |
| Endres, M | 1 |
| Karaiskos, D | 1 |
| Tzavellas, E | 1 |
| Spengos, K | 1 |
| Vassilopoulou, S | 1 |
| Paparrigopoulos, T | 1 |
| Mead, GE | 1 |
| Hsieh, CF | 1 |
| Lee, R | 1 |
| Kutlubaev, MA | 1 |
| Claxton, A | 1 |
| Hackett, ML | 1 |
| Rampello, L | 1 |
| Chiechio, S | 1 |
| Nicoletti, G | 1 |
| Alvano, A | 1 |
| Vecchio, I | 1 |
| Raffaele, R | 1 |
| Malaguarnera, M | 1 |
| Søndergaard, MP | 1 |
| Jarden, JO | 1 |
| Martiny, K | 1 |
| Simis, S | 1 |
| Nitrini, R | 1 |
| Beyenburg, S | 1 |
| Schönegger, K | 1 |
| Møller, M | 1 |
| Gjedde, A | 1 |
| Giacobbe, P | 1 |
| Flint, A | 1 |
| Bilge, C | 1 |
| Koçer, E | 1 |
| Koçer, A | 1 |
| Türk Börü, U | 1 |
| Starkstein, SE | 1 |
| Mizrahi, R | 1 |
| Power, BD | 1 |
| Hegel, M | 1 |
| Hagebeuk, EE | 1 |
| Tans, JT | 1 |
| de Regt, EW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Double Blind Trial to Compare the Efficacy and Safety of Escitalopram With Placebo in Patients With Acute Stroke for the Prevention of Poststroke Depression and Related Symptoms (Emotional Incontinence, Anger Proneness), and for Improvement[NCT01278498] | Phase 4 | 444 participants (Anticipated) | Interventional | 2011-01-31 | Active, not recruiting | ||
| Clinical Study Evaluating the Efficacy of Nitazoxanide and Escitalopram as Adjuvant Therapies in Patients With Rheumatoid Arthritis[NCT05480878] | Phase 3 | 90 participants (Actual) | Interventional | 2022-12-02 | Completed | ||
| The Efficacy of Citalopram Treatment in Acute Stroke[NCT01937182] | Phase 2 | 642 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Escitalopram and Language Intervention for Subacute Aphasia (ELISA)[NCT03843463] | Phase 2 | 88 participants (Anticipated) | Interventional | 2021-07-18 | Recruiting | ||
| FLOW Trial: Fluoxetine to Open the Critical Period Time Window to Improve Motor Recovery After Stroke[NCT03448159] | Phase 2 | 52 participants (Actual) | Interventional | 2019-01-01 | Completed | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Agomelatine in the Prevention of Poststroke Depression[NCT05426304] | Phase 4 | 420 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | ||
| Prevention of Post-Stroke Depression - Treatment Strategy[NCT00071643] | 201 participants (Actual) | Interventional | 2002-09-30 | Completed | |||
| Establishing the Effect(s) and Safety of Fluoxetine Initiated in the Acute Phase of Stroke[NCT02683213] | Phase 3 | 1,500 participants (Actual) | Interventional | 2014-10-20 | Completed | ||
| Effect of Serotonin and Levodopa Functional Recovery in Patients With Cerebral Infarction[NCT02386475] | Phase 4 | 39 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for citalopram and Stroke
| Article | Year |
|---|---|
Safety and Efficacy of SSRIs in Improving Poststroke Recovery: A Systematic Review and Meta-Analysis.
Topics: Anxiety; Citalopram; Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors; Stroke; United Sta | 2022 |
Comparative efficacy of nine antidepressants in treating Chinese patients with post-stroke depression: A network meta-analysis.
Topics: Antidepressive Agents; China; Citalopram; Depression; Depressive Disorder, Major; Humans; Network Me | 2020 |
Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis.
Topics: Citalopram; Depression; Fluoxetine; Fractures, Bone; Humans; Selective Serotonin Reuptake Inhibitors | 2021 |
Efficacy and Safety of Citalopram for the Treatment of Poststroke Depression: A Meta-Analysis.
Topics: Antidepressive Agents, Second-Generation; Chi-Square Distribution; Citalopram; Depression; Humans; O | 2018 |
Efficacy and Safety of Citalopram in Treating Post-Stroke Depression: A Meta-Analysis.
Topics: Citalopram; Depression; Humans; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhib | 2015 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Antidepressant therapy in post-stroke depression.
Topics: Antidepressive Agents; Citalopram; Controlled Clinical Trials as Topic; Depressive Disorder; Humans; | 2008 |
28 trials available for citalopram and Stroke
| Article | Year |
|---|---|
Clinical efficacy of Danzhi Xiaoyao Powder in the treatment of post-stroke depression: A protocol for randomized, double-blind clinical study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Depression; Double-Blind Method; Drug Th | 2021 |
Effıcacy of cıtalopram on stroke recurrence: A randomızed clınıcal trıal.
Topics: Citalopram; Double-Blind Method; Humans; Selective Serotonin Reuptake Inhibitors; Stroke; Treatment | 2022 |
Impact of prestroke physical activity and citalopram treatment on poststroke depressive symptoms: a secondary analysis of data from the TALOS randomised controlled trial in Denmark.
Topics: Aged; Brain Ischemia; Citalopram; Denmark; Depression; Exercise; Female; Humans; Ischemic Stroke; Ma | 2023 |
Antiplatelet effects of citalopram in patients with ischaemic stroke: A randomized, placebo-controlled, double-blind study.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Citalopram; Double-Blind Method; Female; Humans; Male; Midd | 2019 |
Depressive Symptoms in Stroke Patients: Are There Sex Differences?
Topics: Affect; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Citalopram; Depression; D | 2020 |
Post-Stroke Depressive Symptoms: Varying Responses to Escitalopram by Individual Symptoms and Lesion Location.
Topics: Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Selec | 2021 |
Effects of the prophylactic use of escitalopram on the prognosis and the plasma copeptin level in patients with acute cerebral infarction.
Topics: Acute Disease; Brain Ischemia; Cerebral Infarction; Citalopram; Humans; Stroke; United States | 2020 |
Efficacy of Citalopram on Acute Ischemic Stroke Outcome: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Citalopram; Double-Blind Method; Female; Follow-Up S | 2017 |
The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial.
Topics: Citalopram; Disability Evaluation; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Age | 2018 |
The effect of a single dose of escitalopram on sensorimotor networks.
Topics: Citalopram; Dose-Response Relationship, Drug; Double-Blind Method; Female; Healthy Volunteers; Human | 2018 |
Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS).
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Citalopram; Denmark; Double-Blind Method; Early Medi | 2018 |
Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS).
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Citalopram; Denmark; Double-Blind Method; Early Medi | 2018 |
Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS).
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Citalopram; Denmark; Double-Blind Method; Early Medi | 2018 |
Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS).
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Citalopram; Denmark; Double-Blind Method; Early Medi | 2018 |
Serotonergic Regulation and Cognition after Stroke: The Role of Antidepressant Treatment and Genetic Variation.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Cognition; Cognition Disorders; Denmark; | 2019 |
Prevention of poststroke apathy using escitalopram or problem-solving therapy.
Topics: Aged; Antidepressive Agents, Second-Generation; Apathy; Citalopram; Female; Humans; Male; Mental Dis | 2013 |
Prevention of post-stroke generalized anxiety disorder, using escitalopram or problem-solving therapy.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Cognitive Beha | 2014 |
TALOS: a multicenter, randomized, double-blind, placebo-controlled trial to test the effects of citalopram in patients with acute stroke.
Topics: Brain Ischemia; Citalopram; Double-Blind Method; Follow-Up Studies; Humans; Mental Status Schedule; | 2015 |
Different interventions for post-ischaemic stroke depression in different time periods: a single-blind randomized controlled trial with stratification by time after stroke.
Topics: Aged; Antidepressive Agents, Second-Generation; Brain Ischemia; Citalopram; Depressive Disorder; Fem | 2017 |
Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Double-Blind Method; Drug Ad | 2017 |
Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Double-Blind Method; Drug Ad | 2017 |
Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Double-Blind Method; Drug Ad | 2017 |
Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Double-Blind Method; Drug Ad | 2017 |
Prevention of Poststroke Mortality Using Problem-Solving Therapy or Escitalopram.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Double-Blind Method; Female; | 2017 |
A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients.
Topics: Administration, Oral; Aged; Brain; Citalopram; Dominance, Cerebral; Double-Blind Method; Evoked Pote | 2009 |
[Depressive disorders in patients after stroke].
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antidepressive Agents; Citalopram; Depressive D | 2008 |
Depressive disorders in stroke patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antidepressive Agents; Citalopram; Depressive D | 2009 |
Escitalopram and enhancement of cognitive recovery following stroke.
Topics: Aged; Citalopram; Cognition Disorders; Female; Humans; Male; Neuropsychological Tests; Problem Solvi | 2010 |
Escitalopram and enhancement of cognitive recovery following stroke.
Topics: Aged; Citalopram; Cognition Disorders; Female; Humans; Male; Neuropsychological Tests; Problem Solvi | 2010 |
Escitalopram and enhancement of cognitive recovery following stroke.
Topics: Aged; Citalopram; Cognition Disorders; Female; Humans; Male; Neuropsychological Tests; Problem Solvi | 2010 |
Escitalopram and enhancement of cognitive recovery following stroke.
Topics: Aged; Citalopram; Cognition Disorders; Female; Humans; Male; Neuropsychological Tests; Problem Solvi | 2010 |
Increased frequency of first-episode poststroke depression after discontinuation of escitalopram.
Topics: Aged; Aged, 80 and over; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Humans | 2011 |
Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue.
Topics: Activities of Daily Living; Adult; Aged; Antidepressive Agents; Anxiety; Citalopram; Depression; Dul | 2012 |
Prediction of the response to citalopram and reboxetine in post-stroke depressed patients.
Topics: Adrenergic Uptake Inhibitors; Aged; Analysis of Variance; Case-Control Studies; Citalopram; Depressi | 2004 |
Dose response to adjunctive light therapy in citalopram-treated patients with post-stroke depression. A randomised, double-blind pilot study.
Topics: Aged; Citalopram; Combined Modality Therapy; Depressive Disorder, Major; Dose-Response Relationship, | 2006 |
Serotonin 5HT1A receptor availability and pathological crying after stroke.
Topics: Aged; Binding, Competitive; Brain; Citalopram; Crying; Depressive Disorder; Down-Regulation; Female; | 2007 |
Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial.
Topics: Aged; Citalopram; Depression; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disor | 2008 |
Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial.
Topics: Aged; Citalopram; Depression; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disor | 2008 |
Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial.
Topics: Aged; Citalopram; Depression; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disor | 2008 |
Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial.
Topics: Aged; Citalopram; Depression; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disor | 2008 |
31 other studies available for citalopram and Stroke
| Article | Year |
|---|---|
Delayed citalopram administration reduces brain inflammation and enhances skilled motor function after ischaemic stroke in 'MacGreen' mice.
Topics: Animals; Brain Ischemia; Citalopram; Disease Models, Animal; Encephalitis; Ischemic Stroke; Mice; Ne | 2022 |
A recent clinical trial on efficacy of citalopram to prevent stroke recurrence: unresolved controversies.
Topics: Citalopram; Double-Blind Method; Humans; Selective Serotonin Reuptake Inhibitors; Stroke; Treatment | 2023 |
Does citalopram effectively treat post-stroke depression?: A protocol for systematic review and meta analysis.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depression; Humans; Meta-Analysis as Topic; Re | 2020 |
Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depression; Depre | 2017 |
Serotonin transporter gene polymorphisms may be associated with poststroke neurological recovery after escitalopram use.
Topics: Aged; Citalopram; Female; Genotype; Humans; Male; Middle Aged; Pharmacogenomic Variants; Polymorphis | 2018 |
Efficacy of escitalopram oxalate for patients with post-stroke depression.
Topics: Acupressure; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Female; Humans; | 2018 |
Citalopram attenuated neurobehavioral, biochemical, and metabolic alterations in transient middle cerebral artery occlusion model of stroke in male Wistar rats.
Topics: Animals; Brain; Brain Ischemia; Citalopram; Glutathione; Infarction, Middle Cerebral Artery; Male; M | 2018 |
Which Patients Are Prescribed Escitalopram?: Predictors for Escitalopram Prescriptions and Functional Outcomes among Patients with Acute Ischemic Stroke.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Female; Humans; Logistic Mod | 2018 |
Citalopram enhances neurovascular regeneration and sensorimotor functional recovery after ischemic stroke in mice.
Topics: Animals; Brain Ischemia; Citalopram; Doublecortin Protein; Male; Mice; Mice, Inbred C57BL; Nerve Reg | 2013 |
Laughing at funerals.
Topics: Brain Injuries; Citalopram; Humans; Laughter; Male; Middle Aged; Selective Serotonin Reuptake Inhibi | 2013 |
Expression of genes encoding cytokines and corticotropin releasing factor are altered by citalopram in the hypothalamus of post-stroke depression rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Corticotropin-Releasing Hormone; Cyto | 2013 |
Should I prevent my patient from developing depression after stroke? What is the best available option?
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depression; Humans; Stroke | 2014 |
The Role of the Two-Pore Domain Potassium Channel TREK-1 in the Therapeutic Effects of Escitalopram in a Rat Model of Poststroke Depression.
Topics: Animals; Body Weight; Brain; Cell Proliferation; Citalopram; Depression; Disease Models, Animal; Exp | 2015 |
Sobering news about post-stroke depression.
Topics: Citalopram; Depression; Depressive Disorder; Double-Blind Method; Humans; Stroke | 2017 |
Anhedonia and activity deficits in rats: impact of post-stroke depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Citalopram; Depression; Disease | 2009 |
Escitalopram, problem-solving therapy, and poststroke depression.
Topics: Citalopram; Depression; Depressive Disorder; Humans; Problem Solving; Psychotherapy; Selective Serot | 2008 |
Escitalopram, problem-solving therapy, and poststroke depression.
Topics: Citalopram; Depression; Depressive Disorder; Humans; Problem Solving; Psychotherapy; Selective Serot | 2008 |
Escitalopram, problem-solving therapy, and poststroke depression.
Topics: Citalopram; Depression; Depressive Disorder; Humans; Problem Solving; Psychotherapy; Selective Serot | 2008 |
Escitalopram, problem-solving therapy, and poststroke depression.
Topics: Citalopram; Depression; Depressive Disorder; Humans; Problem Solving; Psychotherapy; Selective Serot | 2008 |
Medication and talk therapy help prevent depression after a stroke. Antidepressants and problem-solving therapy can prevent or delay the onset of post-stroke depression.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Depression; Hu | 2008 |
Pharmacological augmentation of motor recovery after stroke: antidepressants for non-depressed patients?
Topics: Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Depressive Disorder; | 2009 |
Incomplete financial disclosure in a study of escitalopram and problem-solving therapy for prevention of poststroke depression.
Topics: Citalopram; Depressive Disorder; Disclosure; Humans; Psychotherapy; Selective Serotonin Reuptake Inh | 2009 |
Decreased expression of serotonin 1A receptor in the dentate gyrus in association with chronic mild stress: a rat model of post-stroke depression.
Topics: Animals; Citalopram; Dentate Gyrus; Depression; Disease Models, Animal; Down-Regulation; Exploratory | 2009 |
Escitalopram and ischemic stroke: cause or chance association?
Topics: Adult; Citalopram; Depression; Humans; Male; Selective Serotonin Reuptake Inhibitors; Stroke | 2010 |
Escitalopram and ischemic stroke: causal or chance association?
Topics: Adult; Antidepressive Agents; Brain Ischemia; Citalopram; Depressive Disorder; Humans; Male; Stroke | 2011 |
Exofocal dopaminergic degeneration as antidepressant target in mouse model of poststroke depression.
Topics: Animals; Brain-Derived Neurotrophic Factor; Citalopram; Corticosterone; Depression; Disease Models, | 2012 |
Cognitive improvement after treatment of depressive symptoms in the acute phase of stroke.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Citalopram; | 2006 |
Severe bradycardia in a stroke patient caused by a single low dose of escitalopram.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antidepressive Agents, Second-Generation | 2007 |
Pharmacological treatment of post-stroke pathological laughing and crying.
Topics: Antidepressive Agents; Citalopram; Crying; Humans; Laughter; Male; Mental Disorders; Middle Aged; Se | 2007 |
Depression and functional outcome after stroke: the effect of antidepressant therapy on functional recovery.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Citalopram; Depression; Female; F | 2008 |
A stroke patient with a non-convulsive status epilepticus during citalopram therapy.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Female; Humans; Status Epile | 2002 |